Annamycin Shows Strong Cardiac Safety in Pooled Analysis, Reinforcing Differentiated Profile

summarizeSummary

Moleculin Biotech reported strong cardiac safety data for its lead drug Annamycin at ASCO 2026, addressing a major limitation of anthracycline chemotherapy and bolstering its ongoing pivotal trial.

check_boxKey Events

• Positive Cardiac Safety Data for Annamycin

  A pooled analysis across five completed clinical trials demonstrated no detectable cardiotoxicity for Annamycin, even at cumulative exposure levels far exceeding conventional anthracycline limits.

• Independent Validation by Cleveland Clinic

  The cardiac safety findings were independently reviewed by Cleveland Clinic cardiology specialists, providing external validation.

• Reinforces Ongoing Pivotal Trial

  This data strengthens the rationale for the ongoing Phase 2b/3 MIRACLE trial for relapsed/refractory AML, with unblinding of initial data expected in June 2026.

• Addresses Key Anthracycline Limitation

  Annamycin's differentiated cardiac safety profile could allow patients to benefit from anthracycline therapy without the traditional cumulative cardiac burden.

auto_awesomeAnalysis

Moleculin Biotech announced positive cardiac safety data for its lead drug candidate, Annamycin, presented at ASCO 2026. A pooled analysis across five clinical trials showed no detectable cardiotoxicity despite high cumulative exposure, a key differentiator for anthracycline-based therapies. This data, independently reviewed by Cleveland Clinic, significantly de-risks Annamycin and strengthens the rationale for the ongoing pivotal Phase 2b/3 MIRACLE trial, which has unblinding expected in June 2026. For a company with a 'going concern' warning and a need for capital, this positive clinical development is crucial for investor confidence and future financing.